Tango Therapeutics

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.

Tango Therapeutics is dedicated to eliminating cancer with precise and safe medicines that leverage the latest advances in genomic and immunologic science. Our mission is to provide transformative solutions for cancer patients, complement existing therapies, and restore patient health.

Tango Therapeutics envisions a future without cancer where people are living healthy, full lives with our therapies. We seek to be a leader in cancer research and development, one that is working diligently to transform cancer medicines and improve healthcare outcomes.

Tango Therapeutics has been recognized outside of the scientific community for our commitment to cancer research. We have been featured on the Top 50 in Digital Health, 100 Most Influential Leaders of the Cradle to Cradle Society, and 30 under 30 Innovators to Watch in Scientific American.